This pioneering research meticulously sifted through safety reports submitted between April 1, 2022, and December 31, 2024, encapsulating a sizable cohort of 7,654 patients primarily identified as having been treated with Pluvicto®. The temporal distribution of these reports conspicuously indicated a monthly uptrend in AE reporting frequency, signaling an escalating clinical adoption that is paralleled by a growing pharmacovigilance dataset. Demographically, the analysis highlighted a noteworthy subset of patients weighing 90 kilograms or more, corresponding to nearly one-quarter of the cases, underscoring the necessity of weight-based considerations in therapeutic management.

To unravel the complex interface between Pluvicto® administration and patient safety, researchers classified the reported adverse events according to the Medical Dictionary for Regulatory Activities (MedDRA®), enabling a standardized taxonomy based on System Organ Classes (SOCs) and preferred terms (PTs). Out of an initial pool of 649 distinct PTs, 33 statistically significant signals were robustly identified through the convergence of four independent pharmacovigilance algorithms: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS). These signals spanned across 10 SOC categories, with 15 AE signals demonstrating a compelling correlation to the pharmacologic action of Lutetium-177-PSMA-617.

A key insight from the temporal analysis of adverse events was the observation that most AEs manifested within the first three months following treatment initiation, illuminating a critical window for clinical vigilance. Among different organ systems, nervous system disorders were distinctive for their rapid onset, often surfacing within the first 10 days post-administration. This early-onset pattern accentuates the need for heightened neurologic monitoring immediately after treatment, as early detection and intervention could mitigate long-term complications.

Beyond the well-characterized hematologic toxicities traditionally associated with radioligand therapies, the study uncovered consistent high-signal AEs including xerostomia (dry mouth), abnormalities in laboratory tests, and general physical health deterioration. These findings resonate with prior clinical observations but now gain quantitative backing from a comprehensive real-world data environment, reinforcing the multifaceted impact of Pluvicto® on patient health beyond tumor control.

Particular attention is warranted for patients exceeding the 90 kg weight threshold, where the incidence and significance of AEs appeared amplified. This weight-related vulnerability suggests that individualized dosing strategies or enhanced supportive measures may be required to optimize safety profiles for heavier patients. With the increasing global rollout of Pluvicto®, integrating such nuanced clinical insights is paramount to tailoring therapy and mitigating risks.

The rigorous application of disproportionality analysis techniques in this study exemplifies how modern pharmacovigilance leverages large-scale spontaneous reporting systems to generate clinically actionable intelligence. By cross-validating AE signals through multiple statistical algorithms, the research delivers a high degree of confidence in the detected associations, thereby paving the way for improved safety guidelines and patient monitoring protocols.

Moreover, the temporal profiling adds an invaluable dimension to understanding the kinetics of adverse reactions. The identification of distinct early-onset versus delayed-onset toxicities provides clinicians with a temporal roadmap for surveillance and intervention, facilitating proactive patient management rather than reactive treatment of complications.

The study also highlights the indispensable role of laboratory assessments — intensified and diversified screening could preemptively flag subclinical toxicities, allowing timely adjustment of therapy or supportive care. This aligns with modern precision medicine paradigms, where dynamic monitoring underpins safe and effective oncologic treatments.

In conclusion, this robust disproportionality analysis of the FDA’s FAERS database reaffirms the known safety signals linked with Lutetium-177-PSMA-617 while unveiling novel considerations for clinical practice. It advocates for heightened awareness of early neurologic symptoms, comprehensive laboratory screening, and the incorporation of patient-specific characteristics such as body weight into therapeutic decision-making. As Pluvicto® continues to redefine treatment landscapes for advanced prostate cancer, such real-world evidence studies are critical to safeguarding patient outcomes and optimizing the clinical benefit-risk balance.

This investigation offers a template for future pharmacovigilance in oncology, demonstrating how large data repositories and sophisticated analytic frameworks collaboratively enhance drug safety knowledge. Ultimately, these insights bolster clinicians’ capacity to harness the therapeutic potential of novel agents like Pluvicto®, while vigilantly managing their adverse effect profiles in diverse patient populations.

Subject of Research: Adverse events related to Lutetium-177-PSMA-617 (Pluvicto®) in the treatment of metastatic castration-resistant prostate cancer, using data from the FDA’s Adverse Event Reporting System.

Article Title: Adverse events associated with Lutetium-177-PSMA-617 (Pluvicto®) in advanced prostate cancer: a disproportionality analysis based on the FDA’s adverse event reporting system (FAERS).

Article References: Jin, Y., Zhang, Y., Wang, M. et al. Adverse events associated with Lutetium-177-PSMA-617 (Pluvicto®) in advanced prostate cancer: a disproportionality analysis based on the FDA’s adverse event reporting system (FAERS). BMC Cancer 25, 1470 (2025). https://doi.org/10.1186/s12885-025-14846-x

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14846-x

The study, conducted by Zhang et al. and published in BMC Cancer in 2025, provides the most extensive evaluation to date of the hematologic and lymphatic toxicities linked to various CAR-T products, including tisa-cel, axi-cel, brexu-cel, liso-cel, ide-cel, and cilta-cel. By parsing through 1,600 individual case safety reports from August 2017 through December 2023, this analysis delineates the granular spectrum of adverse events that follow CAR-T infusion, shedding light on their incidence, timing, clinical severity, and impact on patient mortality.

CAR-T therapy harnesses the patient’s own immune cells, genetically engineering T lymphocytes to recognize and destroy cancer cells expressing specific antigens, most typically CD19 in B-cell malignancies. Although this mechanism delivers potent antitumor activity, it simultaneously disrupts normal hematopoietic and lymphoid homeostasis. The FAERS data indicate that such disturbances manifest rapidly, with a majority of hematologic complications emerging within 10 days post-infusion, highlighting an acute window of vulnerability.

Among the 25 hematologic and lymphatic AEs identified, several stood out both for their frequency and their profound clinical implications. Most notably, B-cell aplasia exhibited the highest Reporting Odds Ratio (ROR) and Information Component (IC) values, signaling a robust association across all CAR-T products examined. This on-target, off-tumor effect, while an indicator of therapeutic activity, results in prolonged immunodeficiency, predisposing patients to infectious complications that can complicate their treatment course.

Adjacent to B-cell aplasia in terms of significance were cytopenias of varying lineages—pancytopenia, anemia, febrile bone marrow aplasia, and hypofibrinogenemia—each representing facets of marrow suppression or dysregulation. The underlying pathophysiology is multifactorial, attributed to cytokine-mediated inflammation, marrow niche disruption, and collateral immune-mediated toxicity, cumulatively exacerbating patient frailty.

Crucially, the study’s employment of LASSO regression analysis uncovered fifteen adverse events within the hematologic and lymphatic spectrum that bore a statistically significant correlation with mortality. This subclass includes severe but less frequently reported conditions such as splenic hemorrhage and disseminated intravascular coagulation (DIC). These life-threatening events underscore an urgent need for vigilant monitoring and prompt intervention protocols tailored to CAR-T recipients.

The differential association observed with specific CAR-T products revealed that therapies targeting CD19 and those incorporating the CD28 costimulatory domain exhibited a higher propensity for hematologic and lymphatic toxicities. This correlation invites further exploration into how product design—such as antigen specificity and intracellular signaling motifs—influences both efficacy and safety profiles.

While CAR-T therapy often commands attention for its cytokine release syndrome and neurotoxicity, the spotlight on hematologic AEs offered by Zhang et al. shifts the paradigm, emphasizing complications that can persist beyond the acute phase and tangibly influence patient survival. This extended morbidity calls for a multidisciplinary approach encompassing hematologists, oncologists, immunologists, and critical care specialists.

Furthermore, this study raises compelling questions about the current standards for post-CAR-T monitoring. The early onset of cytopenias and coagulopathies suggests that existing surveillance frameworks may need refinement to enable earlier detection and preemptive management, thereby reducing mortality rates associated with these complications.

The formidable figures derived from the FAERS analysis paint a sobering picture: a 15.3% mortality rate tied directly to hematologic and lymphatic system adverse events. Considering the growing adoption of CAR-T therapies worldwide, these findings bear immense clinical significance, underscoring an imperative to integrate risk stratification and personalized supportive care into therapeutic protocols.

Clinicians and researchers alike must now grapple with balancing the undeniable therapeutic promise of CAR-T cells against an evolving toxicity landscape. Innovations aimed at modulating the immunologic milieu, protecting hematopoietic function, or engineering next-generation CAR-T cells with improved safety metrics are avenues of intense ongoing investigation.

Notably, the identification of splenic hemorrhage and disseminated intravascular coagulation as harbingers of mortality prompts the development of targeted guidelines for their recognition and management in patients undergoing CAR-T therapy. Prophylactic strategies and aggressive therapeutic interventions tailored to these rare but fatal complications may enhance overall patient outcomes.

Zhang et al.’s pharmacovigilance approach underscores the value of post-marketing surveillance databases like FAERS in advancing our understanding of real-world CAR-T therapy safety. While clinical trials provide controlled environments, these large-scale databases capture the heterogeneity of patient experiences, comorbidities, and treatment exposures reflective of standard clinical practice.

The study’s methodology—leveraging disproportionality analysis through ROR and IC values—offers a statistically rigorous means of teasing apart drug-event associations from background noise. Such analytical precision is pivotal in distinguishing genuine adverse event signals from coincidental occurrences, fostering actionable insights.

In conclusion, the complex interplay between CAR-T therapy’s potent antitumor efficacy and its disruptive impact on the hematologic and lymphatic systems necessitates heightened awareness and proactive clinical strategies. As CAR-T indications expand beyond hematologic malignancies into solid tumors and other domains, integrating safety data of this magnitude will be integral to maximizing therapeutic benefit while minimizing harm.

Ultimately, the findings reported by Zhang and colleagues offer a critical roadmap for clinicians, researchers, and drug developers navigating the evolving landscape of cellular immunotherapy, illuminating hidden risks and guiding safer deployment of these transformative cancer treatments.

—

Subject of Research: Hematologic and lymphatic system adverse events associated with CAR-T therapy

Article Title: Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database

Article References: Zhang, Z., Zheng, J., Liang, Y. et al. Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. BMC Cancer 25, 846 (2025). https://doi.org/10.1186/s12885-025-14227-4

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14227-4

Keywords: CAR-T therapy, hematologic adverse events, lymphatic disorders, pharmacovigilance, FDA FAERS, B-cell aplasia, cytopenia, splenic hemorrhage, disseminated intravascular coagulation, pancytopenia, mortality, immunotherapy toxicity, LASSO regression analysis